Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Inflammatory Breast Cancer|Male Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
Interventions: DRUG: sunitinib malate|DRUG: paclitaxel|DRUG: doxorubicin hydrochloride|DRUG: cyclophosphamide|BIOLOGICAL: filgrastim|PROCEDURE: therapeutic conventional surgery|OTHER: laboratory biomarker analysis|OTHER: flow cytometry
Sponsor: University of Washington
Collaborators: National Cancer Institute (NCI)